Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced today that it has entered into an ADC platform technology licensing agreement with Sidewinder Therapeutics, Inc. ("Sidewinder") of the United States. Under the licensing agreement, Escugen has granted Sidewinder a global exclusive license to use its ADC technology platform, EZWi-Fit®, for the development of ADC products targeting specific antigens.

On July 11, 2024, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced that the first patient has been dosed in the Phase III clinical trial (ESG401-301) of its independently developed innovative drug, ESG401 Injection. This trial aims to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer that has previously received at least one line of systemic chemotherapy. This significant milestone marks another important achievement in the development process of ESG401 by Escugen.